- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
- 10-K Annual report
- PDF 10-K
- 10.15 2005 Omnibus Incentive Plan, As Amended on December 28, 2007
- 10.21 Separation Agreement Dated July 31, 2007 by and Between NPS Pharmaceuticals, Inc. and Gregory M. Torre
- 10.30 Asset Purchase Agreement, Dated October 9, 2007
- 10.31 Separation Agreement Dated December 7, 2007 by and Between NPS Pharmaceuticals, Inc. and Val R. Antczak
- 10.32 Separation Agreement Dated November 19, 2007 by and Between NPS Pharmaceuticals, Inc. and Gerard J. Michel
- 10.33 Commercial Manufacturing Agreement, Dated October 18, 2002
- 10.33 Amending Agreement, Dated March 15, 2004
- 10.33 Amendment Number One to Amending Agreement
- 12.1 Ratio of Earnings
- 21.1 Subsidiaries
- 23.1 Consent
- 31.1 CEO 302 Certificate
- 31.2 CFO 302 Certificate
- 32 906 Certificate
- 10.15 2005 Omnibus Incentive Plan, As Amended on December 28, 2007
- 10.21 Separation Agreement Dated July 31, 2007 by and Between NPS Pharmaceuticals, Inc. and Gregory M. Torre
- 10.30 Asset Purchase Agreement, Dated October 9, 2007
- 10.31 Separation Agreement Dated December 7, 2007 by and Between NPS Pharmaceuticals, Inc. and Val R. Antczak
- 10.32 Separation Agreement Dated November 19, 2007 by and Between NPS Pharmaceuticals, Inc. and Gerard J. Michel
- 10.33 Commercial Manufacturing Agreement, Dated October 18, 2002
- 10.33 Amending Agreement, Dated March 15, 2004
- 10.33 Amendment Number One to Amending Agreement
- 12.1 Ratio of Earnings
- 21.1 Subsidiaries
- 23.1 Consent
- 31.1 CEO 302 Certificate
- 31.2 CFO 302 Certificate
- 32 906 Certificate
- 10.2 1998 Stock Option Plan Thru December 2007
- 10.2 1998 Stock Option Plan Thru December 2007
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
NPS Pharmaceuticals, Inc.:
We consent to incorporation by reference in the registration statements (Nos. 33-79622, 333-17521, 333-94269, 333-124821, 333-126817 and 333-126823) on Forms S-8 and (Nos. 333-41758, 333-106770, 333-108612, 333-117219, 333-127756, 333-131273 and 333-146235) on Forms S-3 of NPS Pharmaceuticals, Inc. of our reports dated March 14, 2008, with respect to the consolidated balance sheets of NPS Pharmaceuticals, Inc. and subsidiaries as of December 31, 2007 and 2006, and the related consolidated statements of operations, stockholders' deficit and comprehensive loss, and cash flows for each of the years in the three-year period ended December 31, 2007, and the effectiveness of internal control over financial reporting as of December 31, 2007, which reports appear in the December 31, 2007 annual report on Form 10-K of NPS Pharmaceuticals, Inc. Our report dated March 14, 2008, on the effectiveness of internal control over financial reporting as of December 31, 2007, expresses our opinion that NPS Pharmaceuticals, Inc. did not maintain effective internal control over financial reporting as of December 31, 2007 because of the effect of material weaknesses on the achievement of objectives of the control criteria and contains an explanatory paragraph that states that management has identified and included in its assessment at December 31, 2007, material weaknesses related to an ineffective control environment, financial reporting risk assessment process, supervisory and monitoring activities, and policies and procedures with respect to share based compensation, accrued liabilities and interest expense. Our report on the consolidated financial statements refers to the Company's adoption for the provisions of Statement of Financial Accounting Standards No. 123R, "Share-Based Payment," in 2006.
/s/ KPMG LLP
Princeton, New Jersey
March 14, 2008